Trial Profile
A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jun 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Yttrium-90 (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Adverse reactions
- 01 Feb 2022 Results published in the Cancer Biotherapy and Radiopharmaceuticals
- 15 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2020 Planned End Date changed from 1 Jun 2022 to 1 Jan 2023.